9 INTERNATIONAL WORKSHOP ON HIV...

www.virology-education.com

9TH INTERNATIONAL WORKSHOP ON

HIV PEDIATRICSPARIS, FRANCE • 21 - 22 JULY 2017

EVALUATION REPORT

2Evaluation Report - 9th Pediatrics Workshop 21 - 22 July 2017, Paris, France

The 9th HIV Pediatrics Workshop was organized on 21-22 July 2017 in Paris, France. It attracted 299 participants from 39 countries, including 46 young investigators from 16 countries. This high profile workshop brought together all kinds of stakeholders to share research results, important clinical developments and updates on ongoing and new trials in the field of HIV Pediatrics. The program featured plenary sessions, oral abstract presentations, poster discussions, poster walks and poster viewing sessions. The workshop provided an unique opportunity to meet colleagues in a scientific focused setting. Special attention was given to the empowerment of healthcare practitioners from Resourse-Limited settings and young investigators with an accepted abstract who received free registration.

INTENT TO CHANGEThe conference was very well received which is reflected by the evaluation results. 92% of the respondents indicated that the lectures given in this conference have increased their knowledge on HIV Pediatrics, 88% agreed that the program was beneficial for the clinical management of their patients, and 91% reported that they intend to incorporate the new information into the care of their patients.

PROGRAMThe program included 15 invited lectures, 20 oral abstract presentations, 3 regular poster viewing sessions, 4 poster walks, 1 poster discussion session, 2 debates and a case presentation with a discussion panel. Ample time was allocated for discussion. The evaluation scores of the presentations can be found on pages 12 - 19.

ABSTRACTSThe Organizing & Scientific Committee received 190 abstracts, of whom 20 were accepted for the oral presentation, 83 for poster presentations, 4 for poster discussions and 45 for the abstract book only. 38 rejections based on low quality scored by the reviewers (mean number of reviewers per abstract was 11.2)

The respondents confirmed that the scientific content of the abstracts was (highly) relevant to their work (78%) and that the topics were (very) interesting (92%).

FUTUREThe majority of the respondents very much appreciated the conference to such an extent that they would recommend the meeting to their colleagues (98%) and plan to attend the 2018 meeting (94%).

EXECUTIVE SUMMARY

“A must attend workshop! Great cutting edge resources/presentations with ability to network”

“Informative and eye-opening. Great to see current work in the field and HIV pediatrics from around the world.”


Executive Summary .............................................................................. 2

Meeting Description .............................................................................. 5

Meeting Demographics ......................................................................... 7

Organizing Committee (2017) ............................................................... 9

Scientific Committee (2017) ................................................................ 10

Participants’ Feedback ....................................................................... 11

Invited lectures, abstract-driven presentations ..................................12

Meeting objectives ................................................................................20

Learning objectives ...............................................................................20

Conference organization .......................................................................21

General conference experience ............................................................21

Meeting metrics ................................................................................. 22

Conclusion .......................................................................................... 23

Acknowledgements ............................................................................ 24

TABLE OF CONTENTS


BACKGROUNDIn the past decade, there has been an impressive success in the prevention of mother-to-child HIV transmission; however, we have not eliminated the problem of pediatric HIV infection, and much work remains to be done. Research in pediatric, adolescent and maternal HIV infection is often a neglected area at major scientific HIV conferences, yet is critically needed to achieve an AIDS-free generation.

The number of new infections among women of reproductive age has not declined in the last 5 years. While we have highly effective interventions to prevent transmission, implementation has been incomplete. Worldwide, 1.8 million children were living with HIV and 150,000 were newly infected in 2015. Even with continued scale-up of preventive services, it is estimated that 2 million children will need antiretroviral treatment (ART) in 2020. Unfortunately, children are substantially less likely than adults to be diagnosed, and engaged in care, and to access life-saving ART.

Treatment of pediatric HIV infection, particularly of infants and young children, remains complex and problematic. Rapid growth and organ system maturation and the emotional and cognitive changes that occur across the developmental spectrum from infancy through adolescence complicate drug development and administration. Adherence outcomes in children have been less than robust and mental health and behavioral issues are emerging as critical to understand and address to ensure long term treatment success.

Additionally, while fewer infected children are being born, there are increasing concerns about the long-term impact of in utero and postnatal exposures to antiretroviral drugs for those children who escape HIV. Currently an estimated 20% of all infants born in sub-Saharan Africa are HIV- and antiretroviral-exposed during pregnancy and the postnatal period.

Rates of new HIV infections among adolescents are still unacceptably high, particularly in eastern and southern Africa. HIV is the leading cause of death in adolescents in Africa and the second leading cause of death in youth globally. Young people account for half of all new cases of

HIV infection worldwide, with adolescent girls and young women disproportionately affected; in sub Saharan Africa in 2015, three out of four newly infected adolescents aged 15–19 years were girls. Adolescents living with HIV have been a particularly difficult group to reach. Uptake of HIV testing among adolescents has remained low, programs struggle to reach and retain adolescents in care, and adherence to treatment has special challenges for this age group. It is estimated that there are approximately 2.1 million adolescents living with HIV, including close to a million children 10-14 years of age.

The pediatric HIV cure agenda is an important emerging area of research. Early infant diagnosis is increasingly available globally, enabling earlier detection of infection. Providing new exciting opportunities to study acute infection in children and developing promising cure strategies.

MEETING OBJECTIVESThe objectives of this meeting are:

• To provide updates on the latest research on new pediatrics drugs, treatments and cure strategies;

• To understand prevention strategies and their application in high/low resource settings;

• To share results on implementation of PMTCT and pediatric care/treatment.

FORMAT

The workshop uses a number of different interactive formats for learning in addition to standard abstracts and plenary talks, including panel discussions, case presentations, debates and is organized on an annual basis prior to the biennially organized IAS or AIDS Conference. The Organizing and Scientific Committee both represent diverse group of the top researchers in pediatric and maternal HIV infection from around the world. They begin to plan for the meeting in the following year immediately after completion of the current year.

MEETING DESCRIPTION


MEETING DESCRIPTION

In general, each session includes a plenary lecture or a set of related scientific overviews presented by invited speakers who are experts in the subject area, followed by oral abstract presentations in the same topic area. As alternative to the traditional plenary lecture and to provide opportunities to synthesize and share latest developments in the field and bring together individuals from different domains in an engaging interchange, the meeting includes at least one debate on the latest “hot topic” (for example, in 2016 there was a debate on the use of pre-exposure prophylaxis (PrEP) in adolescents; in 2015 a debate on birth HIV testing and another on viral load monitoring; and in 2014 a debate on Option B+), and also has included case presentations, panel discussions, including discussions with youth living with HIV. The debate format has been particularly attractive to participants in past years – during the session the audience has an initial vote on the topic (pro or con), and initial presentations are held by debaters. In addition significant time for audience discussion, one-minute wrap-up from debaters, and repeated voting on the topic will be part of this session– with the “winner” being the debater pro or con who changed the most minds on the topic between the initial and final votes.

UNIQUE WORKSHOP FEATURESWith this workshop we aim to reach the following outcomes:

• Update on research on new pediatric antiretroviral drugs and understanding of different treatment strategies in children; this information will translate into increased quality of life and survival for HIV infected children;

• Understanding of available prevention technologies and their application to prevention of HIV in adolescents in high and low resource settings; this information may translate into preventive interventions for high risk adolescents in different settings;

• Sharing results from the implementation science research to optimally implement proven interventions for prevention of mother-to-child HIV transmission in developing countries, and share research on optimizing the pediatric HIV treatment cascade including transition of HIV-infected adolescents into adult care;

• Understanding risks for HIV transmission in pregnant and lactating women and its implications for the fetus/infant; this will help clinicians to put in place interventions to reduce HIV transmission in pregnant and breastfeeding women and how to manage infants exposed in this manner;

• Understanding complications and comorbidities of long-term HIV infection and its therapy, in order to enable improved management of HIV in children.

TARGET AUDIENCEParticipants includes researchers, clinicians, and industry specialists working in academic settings, hospitals, and Non-Governmental Organizations (NGO). The meeting explicitly supports participation of a diverse community of participants, including women, racial and ethnic minorities, and investigators from low and middle income countries and from a broad scope of disciplines; the Workshop brings together junior and senior investigators across a range of disciplines (pediatrics, adolescent medicine, virology, immunology, pharmacology, obstetrics/gynecology, epidemiology and behavioral sciences) to share learning and experience across the critical content areas including HIV treatment and management, drug development, prevention of mother to child transmission, co-infections and co-morbidities, pediatric cure research and implementation science; the meeting provides an interactive platform for analysis, discussion and debate of new scientific findings as well as an opportunity to consider implications for clinical care and program policy; and finally, by posting all presentations made during the workshop on the website (http://www.infectiousdiseasesonline.com/), study results and state of the art analyses are broadly disseminated beyond the walls of the conference venue to global community.

LEARNING OBJECTIVESAfter attending this meeting the participant will be able:

• To describe the diversity of the HIV pediatric epidemic world-wide;

• To understand optimal treatment & management of HIV infection in infants, children and adolescents;

• To describe major co-infections in HIV-infected children;

• To describe the special issues related to HIV infection in adolescents and programming options for youth.


MEETING DEMOGRAPHICS

NUMBER OF REGISTRATIONS312 registrations from 39 countries.

GEOGRAPHICAL DISTRIBUTION OF REGISTRANTSMost of the atteendees came from United States (21%) followed by South Africa (15%), United Kingdom (9%), France (6%) and Uganda (5%).

United States 66 India 4 Ukraine 2

South Africa 46 Indonesia 4 China 1

United Kingdom 27 Italy 4 DR Congo 1

France 19 Nigeria 4 Ethiopia 1

Uganda 16 Australia 3 Hong Kong 1

Kenya 11 Malawi 3 Madagascar 1

Netherlands 11 Nepal 3 Romania 1

Thailand 10 Senegal 3 Rwanda 1

Zambia 9 Spain 3 Saudi Arabia 1

Cameroon 7 Belgium 2 Serbia 1

Portugal 6 Burkina Faso 2 Turkey 1

Zimbabwe 6 Namibia 2

Mozambique 5 Swaziland 2

PROFESSIONAL BACKGROUND OF REGISTRANTSThe majority of the registrants were medical doctors (41%), followed by researchers (23%). Most of them work in hospitals (22%), followed by NGOs (22%), Universities (21%) and Research Institutes (14%).......................................

NUMBER OF YOUNG INVESTIGATORS46 young investigators joined the workshop this year.

South Africa 14 Cameroon 1 Nepal 1

United States 10 Côte D'ivoire 1 Nigeria 1

United Kingdom 6 Indonesia 1 Senegal 1

Thailand 3 Kenya 1 Serbia 1

France 2 Malawi 1 Uganda 1

Burkina Faso 1


MEETING DEMOGRAPHICS

Type of organization Occupation

N=264 N=266

Area of expertise Average number of patients per year

N=534 N= 127

PERCENTAGE OF RETURNING AND NEW REGISTRATIONS

(University) Hospital (N=59)

22%

NGO (N=59)22%

University (N=55)

21%

Research Institute (N=37)

14%

Other (N=23) 9%

Government Agency (N=19)

7%

Industry (N=12)5%

Medical doctor (MD)

(N=109)41%

Researcher (PhD) (N=60)

23%

Other (N=45)17%

Pharmaceutical Company (N=11) 4%

Healthcare Practitioner (N=10) 4%

Nurse (N=10)4%

Student (N=8)3%

Health Administrator

(N=7) 3%

Policy maker (N=6)

2%

HIV (N=245)46%

Pediatrics (N=160)30%

Other (N=42)8%

Hepatitis (N=38)7%

Immunology (N=20)

4%

Gynecology (N=16)

3%

Pharmacology (N=14)

2%

None, (N= 36) 28%

151-200, (N=30) 24%

1-50, (N=25) 20%

1-50, (N=15) 11%

51-100, (N=8) 6%

201-250, (N=8) 6%

101-150, (N=6) 5%

Returning participant(N=85) 54%

New Participant(N=72) 46%

9Evaluation Report - 9th pediatrics Workshop 21 - 22 July 2017, Paris, France

ORGANIZING COMMITTEE

Elaine Abrams MD

ICAP Mailman School of Public Health, Colombia

University, USA

Mark Cotton MD, PhD

Stellenbosch University, South Africa

Carlo Giaquinto MD

University of Padova, Italy

Charles Boucher MD, PhD

Erasmus Medical Center, Rotterdam,

The Netherlands

Jintanat Ananworanich MD, PhD

The US Military HIV Research Program,

USA

Albert Faye MD

University Paris Diderot/ Hôpital Robert Debré,

France

Lynne Mofenson MD

Elizabeth Glaser Pediatric AIDS Foundation, USA

Edmund Capparelli PharmD

University of California, USA

Patricia Flynn MD

St. Jude Children's Hospital USA

Victor Musiime MBCHB, MMED, PhD Makerere University,

Uganda

Diana Gibb MD, MRCP, MSC

Medical Research Council, United Kingdom

Valériane Leroy MD

Inserm France

Gareth Tudor-Williams MD

Imperial College London United Kingdom

10Evaluation Report - 9th pediatrics Workshop 21 - 22 July 2017, Paris, France

SCIENTIFIC COMMITTEE

Moherndran Archary, MBChB, DOH, FCPaeds - University of KwaZulu Natal, South Africa

Jason Brophy, MD - Children's Hospital of Eastern Ontario, Canada

Tsungai Chipato, MBChB - University of Zimbabwe College of Health Sciences, Zimbabwe

Polly Clayden - HIV i-Base, United Kingdom

Anita De Rossi, PhD - AIDS Reference Center, Italy

Marinella Della Negra, MD - Hopital Emilio Ribas, Brazil

Brian Eley, MD - Red Cross Children's Hospital, Department of Pediatrics, South Africa

Rashida Ferrand, MBBS, MRCP, MSc, DRM&H - London School of Hygiene & Tropical Medicine, United Kingdom

Devasena Gnanashanmugam, MD - National Institutes of Health, USA

Tessa Goetghebuer, MD - Hôpital St Pierre, Belgium

Ellen Chadwick, MD - Childrens Memorial Hospital, USA

Shirin Heidari, PhD - European Association of Science Editors, United Kingdom

Chewe Luo, MD, PhD - UNICEF, USA

Dorothy Mbori-Ngacha, MBChB, MMed, MPH - United Nations Children's Fund, South Africa

Philippa Musoke, MD - Makerere University & Johns Hopkins University Research Collaboration, Uganda

Sharon Nachman, MD - SUNY Health Science Center Stony Brook, USA Julie Nelson, MD - Retrovirology Core Laboratory, UNC, USA

Paul Palumbo, MD - Dartmouth-Hitchcock Medical Center, USA

Martina Penazzato, MD, DTMH, MSc, PhD - WHO, United Kingdom

Jorge Pinto, MD, DSc - School of Medicine, Federal University of Minas Gerais, Brasil

Thanyawee Puthanakit, MD - Chulalongkorn University, Thailand

Natella Rakhmanina, MD, PhD, FAAP, AAHIV - Children's National Medical Center, USA

Theodore Ruel, MD - University of California, San Francisco, USA

George Siberry, MD, PhD - National Institutes of Health, USA

Annette Sohn, MD - TREAT Asia/amfAR, Thailand

Lynda Stranix-Chibanda, MBChB, MMED - University of Zimbabwe, Zimbabwe

Graham Taylor, MD - Imperial College, United Kingdom

Claire Thorne, BA, MSc, PhD - University College London, United Kingdom

Marissa Vicari - International AIDS Society, Switzerland

Rachel Vreeman, MD, MS - Indiana University, USA


PARTICIPANTS’ FEEDBACK

NUMBER OF PARTICIPANTS PER SESSION NUMBER OF RESPONDENTS PER DAYDay 1 Day 2

AMSession 1: 260 Session 3: 158

Session 1: 240 Session 3: 220

PMSession 2: 213 Session 4: 185

Session 2: 205 Session 4: 178

Day 1 Day 2

N= 193 N= 181

N= 152 N= 129

BACKGROUND OF RESPONDENTS49% of the respondents worked mainly as a medical doctor, 38% were researchers and 12% were documented as ”other”. 62% of the respondents are involved in daily care of HIV in pediatrics, followed by HIV in general (25%), Infectious disease (7%) and “other” (6%).

Type of organization Occupation

Area of expertise

NUMBER OF PARTICIPANTS 299 participants.

University, (N=75) 43%

Hospital, (N=39) 23%

NGO, (N=30) 17%

Government; (N=12) 7%

OtherN=10) 6%

Pharmaceutical Company, (N=8)4%

Medical Doctor,(N=90) 49%

Researcher, (N=68)38%Other,

(N=12) 7%

Nurse, (N=4) 2%

Pharmacist,(N=4) 2%

Student, (N=2) 1%

HIV in Ped(N=40) 62%

HIV in general(N=101) 25%Infectious

Diseases management

(N=11)7%

Other(N=10) 6%


INVITED LECTURES, ABSTRACT-DRIVEN PRESENTATIONS

FRIDAY JULY 21 Session 1: Pediatric Treatment and Management N=193

Latest Estimates for Pediatric/Adolescent HIV Prevalence and Coverage Mary Mahy, ScD, MHSc UNAIDS, Switzerland

(Strongly) Agree

Neutral (Strongly) Disagree

N/A

Topic is interesting 94% 4% 2% 20

Content is relevant to my work

92% 5% 3% 22

What Have We Learned from the ACT Initiative – Identifying and Treating Children with HIV Infection George Siberry, MD, MPH, FAAP, FPIDS OGAC, PEPFAR, USA

(Strongly) Agree


N/A



84% 14% 2% 23

The Hidden Pediatric HIV Epidemic in Eastern Europe Natella Rakamania, MD, PhD, FAAP, FCP, AAHIVS Children’s National Medical Center / EGPAF, USA

(Strongly) Agree


N/A


Content is relevant to my work 62% 25% 13% 23

Challenges and Triumphs of Pediatric HIV Care and Treatment in West/Central Africa Didier Ekouevi, MD, PhD Inserm, Cote d’Ivoire

(Strongly) Agree


N/A



Debate: Integrase Inhibitors Albert Faye, MD University Paris Diderot/ Hôpital Robert Debré, France Victor Musiime, MBCHB, MMED, PhD Makerere University, Uganda

(Strongly) Agree


N/A






Abstract driven presentations

Comparing Conventional to Point-of-Care (POC) Early Infant Diagnosis (EID): Pre and Post Intervention Data from a Multi-country Evaluation

Jennifer Cohn, O_01

(Strongly) Agree


N/A



Virological Dynamics in HIV-Infected Infants Following Very Early Antiretroviral Treatment

Renate Strehau, O_02

(Strongly) Agree


N/A



Characteristics and Outcomes of Infants Initiating Early Antiretroviral Therapy in South Africa, 2006-2016 – The International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration.

Victoria Iyun, O_03

(Strongly) Agree


N/A



Age-Stratified Rates of Mortality and Key Clinical Events in Youth Aged 0-24 Years in the Multiregional IeDEA Network

Sophie Desmonde, O_04

(Strongly) Agree


N/A



Incidence of Virological Failure to First-Line ART among Children in Europe and Thailand

Ruth Goodall, O_05

(Strongly) Agree


N/A



Multi-Month Prescription of Antiretroviral Therapy and its Feasibility - Experiences from the Baylor International Pediatric AIDS initiative (BIPAI) in Six Southern African Countries

Maria Kim, O_06

(Strongly) Agree


N/A



POSTER VIEWING N=152(Strongly)

AgreeNeutral (Strongly)

DisgreeN/A

The poster session was a valuable element in the program.

93% 6% 1% 32

The combination of poster session and break was well scheduled.

74% 14% 12% 28


Session 2: Models and Comorbidities/Coinfections N=152

Using Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines and Cure Ann Chahroudi, MD, PhD Emory University, Atlanta, USA

(Strongly) Agree


N/A



56% 27% 17% 10

Speaker performance 94% 4% 2% 4

Viral Hepatitis Mother-to-Child Transmission: Applying Lessons from HIV to HBV/HCV Monique Andersson, MD Stellenbosch University / University of Oxford, South Africa / UK

(Strongly) Agree


N/A



70% 20% 10% 7


Viral Hepatitis Mother-to-Child Transmission: Applying Lessons from HIV to HBV/HCV Gareth Tudor-Williams, MD Imperial College, London, UK

(Strongly) Agree


N/A



76% 15% 9% 14


Viral Hepatitis Mother-to-Child Transmission: Applying Lessons from HIV to HBV/HCV Linda Barlow, MD, MPH MUJHU Research Collaboration, Uganda

(Strongly) Agree


N/A



78% 13% 9% 11

Discussion Topic is interesting 95% 3% 1% 8


80% 12% 8% 12



Structured and Culturally-Relevant Disclosure Intervention Improves Pediatric HIV Disclosure in Ghana: The SANKOFA Experience

Elijah Paintsil, O_07

(Strongly) Agree


N/A



Growth Evolution and Stunting among HIV-Infected Adolescents in the Multiregional IeDEA Cohort Consortium

Julie Jesson O_08

(Strongly) Agree


N/A



81% 15% 4% 16

Structural Brain Changes and Associations in Perinatally Infected Younger Adolescents in CTAAC

Jacqueline Hoare, O_09

(Strongly) Agree


N/A



Poster Discussion

Impacts of Vitamin D and Calcium Supplementation on Bone Mineral Density among Perinatally HIV-Infected Adolescents: A 48-week Randomized Clinical Trial

Tavitiya Sudjaritruk, O_61

(Strongly) Agree


N/A



Early Clinical and Social Outcomes at and after Transfer from Pediatric to Adult HIV Care in Asia

Annette Sohn, O_107

(Strongly) Agree


N/A



Endothelial Dysfunction in HIV-Infected Children

Sahera Dirajlal-Fargo, O_63

(Strongly) Agree


N/A



Does HIV-Related Vascular Stiffening Improve or Deteriorate with Accumulating Time on ART? Data from the CHER Trial Cohort

Steve Innes, O_62

(Strongly) Agree


N/A



71% 21% 8% 27



INVITED LECTURES, ABSTRACT-DRIVEN PRESENTATIONSSATURDAY JULY 22Session 3: Models and Comorbidities/Coinfections N=181

The Final Frontier for eMTCT: Acute HIV Infection During and After Pregnancy Alison Drake, MPH, PhD University of Washington, USA

(Strongly) Agree


N/A



89% 7% 4% 23

New Therapeutic Approaches to ART in Pregnancy Laurent Mandelbrot, MD, PhD Université Paris-Diderot, France

(Strongly) Agree


N/A



88% 7% 5% 14


Pregnancy and Neonatal Outcomes following Prenatal Exposure to Dolutegravir

Claire Thorne, O_07

(Strongly) Agree


N/A



Intensification of Antiretroviral Treatment with Raltegravir for Late-Presenting HIV-Infected Pregnant Women

Thanyawee Puthanakit, O_08

(Strongly) Agree


N/A



Is Tenofovir Use in Pregnancy Associated with Preterm Delivery? A Canadian Perinatal HIV Surveillance Program Analysis

Jason Brophy, O_09

(Strongly) Agree


N/A



Hepatotoxicity in HIV+ Postpartum Women Initiating Efavirenz-Containing Regimens

Patricia Flynn, O_07

(Strongly) Agree


N/A



Asymptomatic Hematologic Toxicity Associated with Very Early Combination Antiretroviral Therapy (cART) in In Utero HIV-infected Infants

Ellen Chadwick, O_08

(Strongly) Agree


N/A




Session 3: Models and Comorbidities/Coinfections N=181

HIV -Affected but Not Infected – The Dilemma of HIV-Exposed but Uninfected Infants Kate Powis, MD, MPH, MBA Botswana Harvard AIDS Institute Partnership, USA

(Strongly) Agree


N/A

Very Good Good Average



87% 9% 4% 16


The Population Effect of HIV Exposure in HIV-Uninfected Children on Infant Mortality in Botswana and South Africa

Amy Slogrove, O_15

(Strongly) Agree


N/A



Developmental Outcomes of Breastfed, HIV-Exposed Uninfected and Breastfed, HIV-Unexposed Children in the Context of Universal Maternal Antiretroviral Therapy: a Prospective Cohort

Stanzi Le Roux, O_16

(Strongly) Agree


N/A




Session 4: Adolescent HIV N=129

The Second Generation: Pregnancy in Women with Perinatally Acquired HIV Jennifer Jao, MD, MPH Icahn School of Medicine at Mount Sinai, USA

(Strongly) Agree


N/A



80% 14% 6% 3


Inequality in Outcomes for Adolescents Living with Perinatally-Acquired HIV in sub-Saharan Africa: a Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Cohort Collaboration Analysis.

Marcel Yotebieng, O_17

(Strongly) Agree


N/A



Attrition and Treatment Outcomes among Perinatally and Behaviourally HIV-Infected Adolescents and Youths in Thai National AIDS program.

Sirinya Teeraananchai, O_18

(Strongly) Agree


N/A



What Constitutes Adolescent-Friendly Health Services? Clinic Characteristics that Attenuate Internalised HIV Stigma among Adolescents Living with HIV.

Marija Pantelic, O_19

(Strongly) Agree


N/A



Experiences of Transition to Adult Care and Readiness to Self-Manage Care in Young People with Perinatal HIV in England.

Ali Judd, O_20

(Strongly) Agree


N/A




Session 4: Adolescent HIV N=129

Debate: Self-Testing Should be Implemented for All Adolescents Pro - Cheryl Johnson World Health Organization, Switzerland Con - Gabriel Chamie, MD, MPH University of California, USA

(Strongly) Agree


N/A



86% 11% 3% 6

Global Examples of Adolescent Friendly Programs - Short Overview

Nicole Willis Africaid, Zvandiri, Zimbabwe

Claude Mellins, PhD Columbia University Medical Center, USA

Catherine Dollfus , MD, MPH University of Paris-Diderot, France

(Strongly) Agree


N/A



68% 19% 10% 21

Adolescent view Manuella & Josephine

(Strongly) Agree


N/A



92% 7% 2% 37



MEETING OBJECTIVES N=129

(Strongly) Agree Neutral (Strongly) Disagree N/A

To provide updates on the latest research on new pediatrics drugs, treatments and cure strategies

90% 7% 3% 9

To understand prevention strategies and their application in high/low resource settings

88% 10% 2% 9

To share results on implementation of PMTCT and pediatric care/treatment

95% 3% 2% 9

LEARNING OBJECTIVES N=129

(Strongly) Agree Neutral (Strongly) Disagree N/A

To describe the diversity of the HIV pediatric epidemic world-wide;

95% 3% 2% 5

To understand optimal treatment & management of HIV infection in infants, children and adolescents

87% 10% 3% 7

To describe major co-infections in HIV-infected children

69% 25% 6% 5

To describe the special issues related to HIV infection in adolescents and programming options

for youth

95% 3% 2% 5



CONFERENCE ORGANIZATION N=152

(Very) Good Average (Very) Poor N/A

Content of electronic announcements (VE newsletters)

91% 5% 4% 23

Frequency of electronic announcements (VE newsletters)

88% 8% 4% 24

Information on the conference website 92% 5% 3% 18

Online registration process 94% 2% 4% 23

Online abstract submission process 95% 4% 1% 58

Meeting venue 97% 2% 1% 15

Meeting room 97% 2% 1% 13

Audiovisuals 96% 3% 1% 17

Food & Beverage 89% 7% 4% 13

Onsite logistics 92% 5% 3% 14

Service level of Conference Secretariat 96% 2% 2% 23

GENERAL CONFERENCE EXPERIENCE N=181

(Very) Good Average (Very) Poor N/A

Overall event experience 98% 2% 0% 11

Opportunity of networking 89% 10% 1% 14

Content of the educational activity 94% 5% 1% 12

Time allocation for discussion 94% 4% 2% 12

Time allocation per presentation 97% 2% 1% 14

No commercial bias (product selling) perceived 94% 4% 2% 18

I would recommend this educational event to my peers 98% 1% 1% 17

I plan to attend this event next time 94% 5% 1% 18


I was motivated to attend this meeting because of:

Multiple answers were allowed. N=549 (answers) out of 193 feedback forms

Scientific program, (N=130) 24%

Meeting Objectives, (N=95) 17%

Opportunity to meet

colleagues, (N=79) 14%Prior to

IAS , (N=55)

10%Faculty/Speakers,

(N=51) 9%

Experience from previous meeting, (N=44) 8%

Meeting location, (N=36) 7%

Free registration Grantee, (N=20) 4%

CME Credits, (N=15) 3%

Free reg YIF(N=15), 3%

Other, (N=9) 2%

MEETING METRICS

How did you become aware of this conference:

Multiple answers were allowed. N=215 (answers) out of 193 feedback forms

VE newsletter(N=85) 39%

Referred by colleague

(N=78) 36%Faculty members

(N=26) 12%

Society Newsletter(N=10) 5%

Flyer at VE meetings(N=10) 5%

Flyer at non VE meetings(N=4) 2%

Industry(N=1) 1%


The Organizing Secretariat is pleased with the results of the 9th Internation Workshop on HIV

Pediatrics. Most of the participants were impressed by the quality of the scientific content and

the time allocated for the discussions. The majority also reported that they were satisfied with

the overall meeting logistical arrangements and agreed it was a well-organized event. Both the

evaluation results and the participants’ feedback strongy lindicated the success and the importance

of this conference. The Organizing Secretariat will invite the Organizing Committee to further

discuss the preparation and the development of the scientific program for the 10th edition in 2018,

which is scheduled to take place in Amsterdam from 20 to 21 July, 2018.

CONCLUSION

“Very beneficial for both researchers & clinicians”

“Brilliant”


The organizer acknowledges the contributions of the following supporters that have made the

9th International Workshop on HIV Pediatrics possible:

ACKNOWLEDGEMENTS

SPONSORS

TITANIUM LEVEL

GOLD LEVEL

SUPPORTER LEVEL CONTRIBUTOR LEVEL

ENDORSERS

SILVER LEVEL

www.virology-education.com

Date post:	29-Dec-2019
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

9 INTERNATIONAL WORKSHOP ON HIV...

Documents